Amid Brexit Chaos, UK PM Promises More R&D Funding, Lower Taxes, And Other Pro-Innovation Measures
The UK prime minister has promised more government R&D funding and other incentives in an attempt to reassure businesses worried by the uncertainty created by the Brexit vote. The move comes shortly before the Chancellor’s autumn statement and the next meeting of the UK EU Life Sciences Steering Group.
You may also be interested in...
Faced with a predicted sharp decline in economic growth as a result of the Brexit vote, the UK Chancellor of the Exchequer has fleshed out proposals for supporting R&D and innovation that have been welcomed by the biopharmaceutical industry.
Liam Fox, one of the ministers in charge of leading the UK out of the EU, does not want the country to stay within the wider European drug regulatory system, even though many in the life science sector see this as vital if regulatory divergence and drug marketing delays are to be avoided.
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.